Jacob Guo, Director of Nucleic Acid R&D at GenScript, will present these findings during a live webinar on October 9, 2026. The research addresses a critical bottleneck in genetic engineering: balancing high editing performance with the stringent requirements of chemistry, manufacturing, and controls. While previous efforts to stabilize the 3' moiety of pegRNAs often relied on lengthening the sequences—complicating production and analytical processes—the new approach focuses on optimizing modification combinations within the standard 130–150nt range.

Testing confirmed that these optimized pegRNAs exhibit superior cytoplasmic stability compared to traditional configurations involving 2'-OMe and phosphorothioate modifications. This increased resilience translated into improved editing outcomes across a variety of test subjects, including HEK293T, HepG2, Jurkat, and primary T cells. The upcoming session by Xtalks intends to provide researchers with actionable insights into how these structural refinements can support more robust prime editing workflows and streamline the development of future genetic therapies.